首页 | 本学科首页   官方微博 | 高级检索  
     

应用组织芯片研究人肾癌中Survivin、EGFR和PCNA的表达与预后的关系
引用本文:柯莽,周涛,王天济,翁志梁. 应用组织芯片研究人肾癌中Survivin、EGFR和PCNA的表达与预后的关系[J]. 浙江临床医学, 2007, 9(12): 1590-1592
作者姓名:柯莽  周涛  王天济  翁志梁
作者单位:1. 浙江省台州医院,317000
2. 温州医学院附属第一医院,325003
摘    要:目的检测Survivin、EGFR和PCNA在人肾癌组织中的表达,以探讨三者在肾癌中表达的相关性及其与预后的关系。方法利用组织芯片技术构建82例肾癌与26例癌旁正常肾组织芯片,应用免疫组织化学Envision法检测Survivin、EGFR和PCNA在肾癌组织中的表达。结果肾癌中Survivin、EGFR和PCNA的总表达率分别为74.4%(61/82)、57.3%(47/82)和78.0%(64/82),显著高于正常肾组织(P〈0.05)。Survivin和PCNA在肾癌中的表达随着病理分级升高而升高,Survivin和EGFR在肾癌中的表达随着临床分期的升高而升高。肾癌的预后与Survivin、EGFR的阳性表达率有关(P〈0.05)。Survivin、EGFR、PCNA三者在肾细胞癌的发生发展中关系密切(P〈0.01)。结论Survivin、EGFR、PCNA在肾癌中均有过量表达,可能参与肾癌的发生、发展。Survivin、EGFR阳性表达均可以提示肾癌的不良预后。

关 键 词:肾细胞癌  组织芯片  免疫组织化学  Stwvivin  EGFR  PCNA

Study on the expression of survivin 、 EGFR and PCNA in human renal cell carcinoma(RCC) tissues using tissue microarray
Abstract:Objective To measure the expression of Survivin , EGFR and PCNA in human renal cell carcinoma(RCC) tissues , their correlations and their relationship with prognoses , Methods the RCC tissue microarrays containing 82 cases' specimen were used to determine Survivin and EGFR and PCNA expression by immunohistochemistry. Results The expression rates of survivin ,EGFR and PCNA were 74.39%(61/82) and 57.31%(47/82) and 78.04% (64/82) respectively . The expression rate of survivin, EGFR and PCNA in 82 cases of human RCC tissues were significantly higher than those in 26 cases of corresponding antologous normal kidney tissues( P 〈 0.05 ). The expression of surviving and PCNA got higher as the pathological diagnosis ranked worse ,and the expression of surviving and EGFR were higher in the late stage than early stage of RCC. Conclusion Survivin , EGFR and PCNA are all over- expressed in human RCC , which might be related to RCC' s development . Expression of survivin and EGFR shows poor prognosis in patients with RCC.
Keywords:renal cell carcinoma Tissue microarray Immunohistochemistry Survivin EGFR PCNA
本文献已被 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号